LFST LifeStance Health Group, Inc.
Services-Health Services · Nasdaq · SEC CIK 1845257 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.6%
TTM net income YoY888.7%
TTM EPS YoY884.0%
Revenue 3-yr CAGR18.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin6.2%
Net margin4.3%
FCF margin10.7%
EBITDA margin8.8%
Returns
ROE4.8%
ROA3.3%
ROIC (approx.)5.4%
Asset turnover0.77x
Leverage & solvency
Liabilities / assets31.7%
Debt / equity0.18x
Current ratio1.44x
Interest coverage10.63x
Cash quality & payout
Operating cash flow / net income3.17x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.42B | $1.25B |
| SG&A expense | $382.20M | $363.06M |
| Operating income | $24.15M | -$31.61M |
| Interest expense | $11.66M | $26.54M |
| Pretax income | $12.36M | -$57.61M |
| Income tax | $2.70M | -$170,000 |
| Net income | $9.66M | -$57.44M |
| EBITDA | $65.77M | $9.06M |
| EPS (diluted) | — | — |
| Weighted avg. shares (diluted) | 391.14M | 379.15M |
| Balance sheet | ||
| Cash & equivalents | $248.64M | $154.57M |
| Receivables | $95.71M | $131.80M |
| Current assets | $416.20M | $312.51M |
| PP&E, net | $161.58M | $166.04M |
| Goodwill | $1.29B | $1.29B |
| Intangibles | $177.66M | $190.80M |
| Total assets | $2.20B | $2.12B |
| Current liabilities | $251.96M | $228.89M |
| Short-term debt | $14.50M | $7.25M |
| Long-term debt | $265.93M | $279.79M |
| Total debt | $280.43M | $287.04M |
| Total liabilities | $682.92M | $672.01M |
| Shareholders' equity | $1.52B | $1.45B |
| Net debt | $31.79M | $132.47M |
| Shares outstanding | 388.32M | 382.74M |
| Cash flow statement | ||
| Operating cash flow | $146.15M | $107.26M |
| Capital expenditure | $36.12M | $21.57M |
| Free cash flow | $110.03M | $85.69M |
| Investing cash flow | -$36.12M | -$21.57M |
| Financing cash flow | -$15.96M | -$9.95M |
| Depreciation & amortization | $41.62M | $40.68M |
| Stock-based compensation | $74.70M | $76.17M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.